Business
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner
About this update from Xenon Pharmaceuticals Inc.
[{"type":"text","content":"Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications\nVANCOUVER, British Columbia and BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Darren Cline as Chief Commercial Officer and member of the Xenon senior executive team. In this role, Mr. Cline will lead commercial strategy and operations for the Company’s portfolio of product and development candidates, with initial focus on its lead Phase 3 candidate, azetukalner, and first potential launch in epilepsy. Azetukalner is currently being studied in Phase 3 trials for the treatment of epilepsy and major depressive disorder (MDD), with a Phase 3 trial to be initiated in bipolar depression (BPD) this year. “Darren joins Xenon at a pivotal time with Phase 3 azetukalner data expected in early 2026, paving the way toward regulatory submission and Xenon’s first commercial launch,” said Ian Mortimer, President and Chief Executive Officer of Xenon. “Darren has significant experience in epilepsy and a strong track record of highly successful product launches that brought meaningful medicines to patients and achieved ambitious revenue targets. His experience further strengthens our leadership team and positions us to deliver on the strong potential of azetukalner and our broader pipeline of innovative neuroscience programs.” Mr. Cline is a proven strategic leader with more than 30 years of experience in commercial and launch strategy, marketing, commercial infrastructure and operations, sales, and market access within the biopharmaceutical industry. He most recently served as President and Chief Executive Officer of Epygenix Therapeutics, which focused on developing therapies for rare epileptic encephalopathies. Prior to Epygenix, Mr. Cline was Chief Commercial Officer at GW Pharmaceuticals, where he was instrumental in the successful commercialization of Epidiolex®, contributing to the company’s acquisition by Jazz Pharmaceuticals. Prior to GW, he held multiple positions of increasing responsibility at Seagen, starting as a member of the ...